Vor Biopharma Inc.
$15.71
▲
3.8%
2026-04-21 10:09:01
www.vorbio.com
NMS: VOR
Explore Vor Biopharma Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$810.38 M
Current Price
$15.71
52W High / Low
$65.8 / $2.62
Stock P/E
—
Book Value
$-8.1
Dividend Yield
—
ROCE
-84.67%
ROE
2057.65%
Face Value
—
EPS
$-70.5
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
76
Beta
1.92
Debt / Equity
-0.02
Current Ratio
18.2
Quick Ratio
18.2
Forward P/E
-3.57
Price / Sales
—
Enterprise Value
$303.46 M
EV / EBITDA
-0.9
EV / Revenue
—
Rating
Strong Buy
Target Price
$37.62
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Immunic, Inc. | $0.95 | — | $124.59 M | — | 1572.16% | -16.53% | $1.51 / $0.51 | $-0.06 |
| 2. | Azitra, Inc. | $0.21 | — | $3.48 M | — | -277.12% | -2.31% | $2.66 / $0.1 | $0.35 |
| 3. | LB Pharmaceuticals Inc | $31.67 | — | $875.16 M | — | -9.95% | -15.7% | $30.72 / $13.36 | $11.91 |
| 4. | Aurinia Pharmaceuticals Inc. | $15.96 | 7.38 | $2.12 B | — | 16.2% | 59.91% | $16.54 / $7.29 | $4.39 |
| 5. | C4 Therapeutics, Inc. | $2.99 | — | $284.93 M | — | -32.05% | -44.44% | $3.82 / $1.09 | $2.65 |
| 6. | Champions Oncology, Inc. | $6.08 | — | $84.36 M | — | 57.07% | -47.59% | $9.63 / $5.5 | $0.31 |
| 7. | Vera Therapeutics, Inc. | $41.61 | — | $3.02 B | — | -46.31% | -50.71% | $56.05 / $18.76 | $8.48 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -35.96 M | -28.11 M | -274.28 M | -33.29 M | -31.31 M | — |
| Net Profit | 1.72 B | -812.68 M | -1.57 B | -32.49 M | -30.71 M | — |
| EPS in Rs | 35.27 | -16.64 | -32.22 | -0.67 | -0.63 | -8.05 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -371.64 M | -121.19 M | -126.04 M | -93.42 M |
| Net Profit | -695.98 M | -116.91 M | -117.86 M | -92.09 M |
| EPS in Rs | -14.25 | -2.39 | -2.41 | -1.89 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 464.13 M | 142.89 M | 198.13 M | 299.37 M |
| Total Liabilities | 628.44 M | 46.23 M | 47.4 M | 48.76 M |
| Equity | -164.31 M | 96.66 M | 150.72 M | 250.61 M |
| Current Assets | 458.11 M | 96.51 M | 140.8 M | 236.95 M |
| Current Liabilities | 25.17 M | 18.61 M | 15.57 M | 13.12 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -142.71 M | -99.66 M | -100.29 M | -85.14 M |
| Investing CF | -48.8 M | 96.86 M | 71.01 M | -94.09 M |
| Financing CF | 503.81 M | 53.39 M | 2.94 M | 117.14 M |
| Free CF | -143.65 M | -99.89 M | -101.36 M | -93.61 M |
| Capex | -0.94 M | -0.23 M | -1.07 M | -8.46 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 0.81% | -27.98% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-09-19 | 1:0.05 |